Beyond Willpower: What the Latest Science Means for Your Addiction Treatment Practice

By Oksana Pokoyeva, Billing Department, WCH

The conversation around addiction treatment is shifting — and the pace of that shift is accelerating. A recent research summary published by NIH’s National Institute on Drug Abuse (NIDA) reflects the current scientific consensus: addiction is widely recognized as a brain-based disorder involving measurable neurobiological changes, and the treatment toolkit is expanding in ways that should directly reshape clinical practice.

For providers managing patients with substance use disorders (SUDs), this moment demands attention. Two converging fronts — digital behavioral therapies and GLP-1 receptor agonists — are generating the strongest clinical signals the field has seen in years.

The Scale of the Problem You’re Already Seeing

The numbers contextualize the urgency. Nearly 80,000 Americans died of drug overdoses in 2024 alone. Alcohol use disorder (AUD) contributes to approximately 178,000 deaths annually from injuries, cancer, liver disease, and cardiovascular disease. Tobacco and nicotine addiction account for over 480,000 deaths per year. Intravenous drug use continues to drive HIV and hepatitis C transmission.

These aren’t abstract statistics — they’re patients in your panel, your ED, your outpatient clinic. And the downstream burden is social as well as medical: parental loss from overdoses, childhood trauma, lost productivity. As Dr. Nora Volkow, director of NIDA, has stated, substance use disorders carry a profound impact on individuals, families, and society as a whole.

Despite this scale, the pharmacological options available to providers remain limited. Buprenorphine, methadone, and naltrexone for opioid use disorder; a handful of agents for AUD and tobacco use disorder; and no FDA-approved pharmacotherapies specifically indicated for stimulant or cannabis use disorders. That gap is part of what makes the current research moment so significant.

Reframing the Biology for Your Patients — and Your Team

Before discussing what’s new in treatment, it’s worth reinforcing the neurobiological framework that makes these treatments work. All addictive substances — opioids, alcohol, stimulants, nicotine, cannabinoids — converge on dopaminergic reward pathways, among other neurochemical systems, producing dopamine surges in the nucleus accumbens. These surges generate powerful conditioning signals. The brain encodes the drug as a high-priority reward and begins restructuring itself to seek it automatically in response to environmental cues.

Over time, the reward circuit down-regulates to compensate for repeated overstimulation, reducing baseline hedonic capacity. Meanwhile, prefrontal circuits governing impulse control and stress regulation are progressively weakened. The result is a neurobiological state where craving is amplified, self-regulation is impaired, and the drug becomes the primary available source of reward.

This framework is clinically actionable. It explains why willpower-based approaches fail, why stress is such a powerful relapse trigger, and why treatment must address both the neurochemical imbalance and the behavioral conditioning. It also helps providers have more productive conversations with patients and their families.

Genetics, developmental timing, socioeconomic environment, and social network all modulate risk — but no single factor determines outcome. This means every patient profile is different, and treatment must be individualized accordingly.

CBT in 2026: Effective, But Delivery Matters

Cognitive behavioral therapy remains one of the best-evidenced interventions for SUDs. A major meta-analysis covering 30 randomized controlled trials confirmed that CBT consistently outperforms no treatment or minimal treatment across substance use disorders. However, it did not consistently outperform other evidence-based behavioral treatments.

The practical implication for providers: CBT works, but so do other approaches. If a patient isn’t responding to CBT, switching to another evidence-based modality — motivational enhancement therapy, contingency management, 12-step facilitation — is a clinically reasonable and evidence-supported decision. Persistence through treatment-resistant cases matters.

The more pressing clinical challenge is implementation fidelity. Research demonstrates that how CBT is delivered in practice often diverges substantially from how it was delivered in trials. Training therapists to follow standardized, research-backed protocols is resource-intensive.

A promising solution is CBT4CBT (Computer-Based Training for Cognitive Behavioral Therapy), a web-based program developed at Yale School of Medicine. A randomized clinical trial led by Dr. Brian Kiluk showed that patients receiving CBT4CBT alongside brief weekly clinician check-ins achieved a substantial relative improvement in alcohol-free days at six-month follow-up (approaching 75% compared to pre-treatment baseline) — significantly outperforming both standard outpatient care and in-person CBT alone over the same period. The program is not a replacement for the therapeutic relationship; it’s a scalable, consistent adjunct that reduces variability in skill delivery. For practices operating under resource constraints, this kind of digital augmentation deserves serious consideration.

The GLP-1 Signal: Too Consistent to Ignore

The most striking development in addiction pharmacology right now involves GLP-1 receptor agonists (GLP-1RAs) — the class of drugs including semaglutide (Ozempic/Wegovy), liraglutide, and tirzepatide, already approved for type 2 diabetes and obesity.

The mechanism is logical: GLP-1RAs reduce food cravings partly by modulating dopamine signaling associated with food cues. Since the same dopaminergic pathways govern drug-seeking behavior, the hypothesis that GLP-1RAs might dampen substance cravings is biologically coherent. The evidence is now accumulating from multiple independent directions simultaneously.

In preclinical studies, semaglutide reduced binge-like alcohol drinking in mice and decreased alcohol consumption in alcohol-dependent rats, with measurable changes in brain electrical signaling in regions affected by chronic alcohol exposure.

In large-scale real-world data, a study led by Volkow and Dr. Rong Xu at Case Western Reserve University analyzed records from over 80,000 patients prescribed semaglutide versus non-GLP-1RA medications for obesity. Over 12 months, semaglutide was associated with roughly a 50% lower risk of AUD diagnosis in patients without prior AUD history, and a similarly significant reduction in relapse risk among those with prior AUD — findings that held across gender, race, age, and diabetic status. A second analysis in nearly 600,000 patients with type 2 diabetes replicated these associations. These are observational findings and do not establish causality, but their consistency across independent datasets is clinically meaningful.

Beyond alcohol, emerging but uneven signals extend across multiple substance categories. The alcohol data are the most robust; findings for cannabis, tobacco, and opioids are based primarily on observational data and should be interpreted with appropriate caution. Semaglutide was associated with approximately a 50% reduction in the risk of developing cannabis use disorder and a 34–38% reduction in relapse risk for existing cannabis use disorder. Patients on semaglutide had fewer tobacco use disorder-related encounters, fewer smoking cessation prescriptions, and less cessation counseling. Among patients with opioid use disorder, semaglutide was associated with a lower overdose risk — a preliminary but notable signal.

Critically, a separate analysis confirmed that GLP-1RAs — but not DPP-4 inhibitors, another class of anti-diabetes drugs that work differently — reduced alcohol intake. This specificity strengthens the case for a class-specific mechanism rather than a nonspecific effect.

The first randomized controlled trial of semaglutide for AUD, led by Dr. Christian Hendershot at the University of Southern California, enrolled 48 participants. After eight weeks of dose escalation, those receiving semaglutide consumed significantly less alcohol in controlled drinking sessions, reported fewer heavy drinking days, and had lower weekly craving scores. Among participants who smoked, semaglutide was also associated with reduced cigarette consumption.

The trial was small — but the pattern across species, databases, settings, and countries is, as Dr. Leggio puts it, unusually consistent. Several larger RCTs are now underway, including one at NIDA itself.

What This Means for Clinical Practice Right Now

Providers should not ignore these emerging signals. For patients who already meet approved criteria for diabetes or obesity and also carry a SUD diagnosis or elevated risk, GLP-1RA therapy has plausible dual benefit and an established safety profile — and a careful risk-benefit discussion is warranted. Any clinical use, however, should remain within approved indications and be guided by individualized clinical judgment; GLP-1RAs are not yet approved for SUD treatment, and off-label use requires transparency with patients.

At the same time, GLP-1RAs are not a silver bullet. The mechanism appears to work through craving modulation rather than blocking reward entirely — meaning behavioral and psychosocial supports remain essential components of comprehensive care. The future of addiction treatment is almost certainly combinatorial: pharmacotherapy plus evidence-based behavioral interventions, delivered with fidelity and adjusted iteratively based on patient response.

The NIH research landscape heading into 2026 signals a turning point. The tools are improving. The biology is better understood. And the clinical imperative — to treat addiction as the complex, chronic brain-based disorder it is — has never been clearer.

References

1. National Institutes of Health. Treating addiction: Research leads to more effective medications and psychotherapies. NIH Research Matters, March 24, 2026. https://www.nih.gov/news-events/nih-research-matters/treating-addiction
2. Magill M, Ray L, Kiluk B, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. J Consult Clin Psychol. 2019;87(12):1093–1105. PMID: 31599606.
3. Kiluk BD, Benitez B, DeVito EE, et al. A digital cognitive behavioral therapy program for adults with alcohol use disorder: A randomized clinical trial. JAMA Netw Open. 2024;7(9):e2435205. PMID: 39325452.
4. Chuong V, Farokhnia M, Khom S, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12):e170671. PMID: 37192005.
5. Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548. PMID: 38806481.
6. Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations. Mol Psychiatry. 2024;29(8):2587–2598. PMID: 38486046.
7. Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with tobacco use disorder in patients with type 2 diabetes. Ann Intern Med. 2024;177(8):1016–1027. PMID: 39074369.
8. Farokhnia M, Tazare J, Pince CL, et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J Clin Invest. 2025;135(9):e188314. PMID: 40048376.
9. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405. PMID: 39937469.